May 26 (Reuters) - Prescient Therapeutics Ltd PTX.AX :
* SIGNED EXCLUSIVE GLOBAL LICENSING AGREEMENT WITH TRUSTEES OF UNIVERSITY OF PENNSYLVANIA
* IMMUNE RECEPTOR PLATFORM FOR DEVELOPMENT OF INNOVATIVE CELL THERAPIES
* GOT GLOBAL, NON-EXCLUSIVE LICENCE FROM OXFORD UNIVERSITY TO USE SPYTAG/SPYCATCHER MOLECULAR BINDING SYSTEM